Lu, Linbin; Zhuang, Tingting; Shao, Erqian; Liu, Yanhong; He, Huimin; Shu, Zhimin; Huang, Yan; Yao, Yichen; Lin, Shan; Lin, Shaoqin; Chen, Xi; Chen, Xiong published the artcile< Association of antibiotic exposure with the mortality in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy: A hospital-based retrospective cohort study>, Synthetic Route of 1492-18-8, the main research area is metastatic colorectal cancer bevacizumab chemotherapy antibiotic medication.
Preclin. studies showed that antibiotic exposure played a role in clin. outcomes in patients with chemotherapy via modulation of microbiota. However, it remains unknown whether antibiotic exposure during the bevacizumab therapy affects the clin. outcomes in metastatic colorectal cancer(mCRC) patients. This study aimed to examine the association between the antibiotic medication and the clin. outcomes in mCRC patients with bevacizumab therapy. This retrospective cohort anal. included 147 mCRC patients treated with bevacizumab. The hazard ratio of death was estimated using three Cox proportional hazards models with (1) never vs ever; (2) never vs 1-6 days and 7-40 days;(3) increase per day, and further tested using propensity score matching (PSM) and landmark anal. A smooth curve technique was used to explore the shape of dose-response relationship. Compared with the non-antibiotic group, antibiotic exposure was inversely associated with the mortality in the antibiotic group after adjustment for demog. and other potential confounders (a history of medication: HR, 0.650(95%CI: 0.360 to 1.173); an increase per day: HR, 0.967(CI: 0.924 to 1.011); 1-6 days: HR, 0.859(CI: 0.441 to 1.674); 7-40 days: HR, 0.474(CI: 0.225 to 0.999); P for trend = 0.040). A test for the interaction between sex was statistically significant (p = 0.016). A similar result was found as measured by landmark and PSM anal. Significant neg. dose-response relationship was shown by smooth curve anal. in the male patients but not female after adjustment for confounders(p = 0.028). No association was found between the antibiotic medication and adverse events of bevacizumab. Antibiotic exposure could be inversely associated with the mortality in mCRC patients treated with bevacizumab.
PLoS One published new progress about Antibiotics. 1492-18-8 belongs to class alcohols-buliding-blocks, and the molecular formula is C20H21CaN7O7, Synthetic Route of 1492-18-8.
Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts